Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00630019 · ClinicalTrials.gov registry record · Phase 4

Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator

A Phase 4 study of Cataract, sponsored by Santen.

Completed
Registry status
Phase 4
Development phase
96
Enrollment target
1
Study location

NCT00630019 is a Phase 4 study of Cataract that has completed, run by Santen. The registered enrollment target is 96 participants, below the 227-participant average among 83 other Cataract trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00630019, a Phase 4 study of Cataract, has completed, sponsored by Santen.

COMPLETED
Registry status
Phase 4
Development phase
96 participants
Enrollment target
1
Study location

Study Summary

Compare ocular tissue levels following topical ocular instillation of 1.5% levofloxacin ophthalmic solution or an active comparator in subjects undergoing cataract surgery.

Conditions Studied

Interventions

  • DRUG 1.5% levofloxacin ophthalmic solution
  • DRUG 0.5% moxifloxacin hydrochloride ophthalmic solution

Study Locations (1)

Pennsylvania

  • Bucci Laser Vision & Ambulatory Surgery Center - Wilkes-Barre

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2008-02
Phase Phase 4

Sponsor

Santen

32 total trials

What the Registry Record Tells You About NCT00630019

The ClinicalTrials.gov registry entry for NCT00630019 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 227-participant average among 83 other Cataract trials with a reported enrollment target (58% lower). The listed sponsor is Santen, which has 32 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 2 interventions - of which 1.5% levofloxacin ophthalmic solution is the first listed.

NCT00630019 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT00630019 about?

NCT00630019 is a clinical study titled "Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator". Compare ocular tissue levels following topical ocular instillation of 1.5% levofloxacin ophthalmic solution or an active comparator in subjects undergoing cataract surgery.

What is the current status of trial NCT00630019?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 96 participants. The study started on 2008-02.

What conditions does trial NCT00630019 study?

This clinical trial studies the following conditions: Cataract.

What interventions are being tested in trial NCT00630019?

The interventions under investigation include: 1.5% levofloxacin ophthalmic solution (DRUG), 0.5% moxifloxacin hydrochloride ophthalmic solution (DRUG).

Who is sponsoring clinical trial NCT00630019?

This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00630019 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.